Boosting pigment epithelial-derived factor: a promising approach for the treatment of early portal hypertension by Vespasiani-Gentilucci, U & Rombouts, K
Boosting pigment epithelial-derived
factor: a promising approach for the
treatment of early portal hypertension
Umberto Vespasiani-Gentilucci,1 Krista Rombouts2
Portal hypertension (PHT) is a heteroge-
neous clinical entity which develops in
patients with cirrhosis. It is responsible for
many of the complications that occur in cir-
rhosis, including gastroesophageal varices,
hepatorenal syndrome, ascites, hepatic
encephalopathy and hypersplenism.1 There
are three principal factors responsible for
the development of PHT, namely (1) purely
mechanical obstruction resulting from
hepatic ﬁbrosis and regenerative nodules;
(2) contraction of sinusoidal and perisinu-
soidal contractile cells due to an imbalance
between intrahepatic vasoconstrictory and
vasodilatory mediators and (3) splanchnic
vasodilation and increased portal blood
ﬂow.1 Factors leading to the development
of PHT include hypoxia, oxidative stress,
inﬂammation and shear stress as potential
mediators for the angiogenic response.
Vascular Endothelial Growth factor (VEGF)
is a key mediator in regulating the angio-
genic switch in many pathological condi-
tions, and is also probably a major player in
the neoangiogenic process during the devel-
opment of a hyperdynamic splanchnic
circulation, and the formation of portal-
systemic collateral vessels.2 This has led to
many studies seeking to identify signalling
pathways that interact with, or affect the
formation and action of VEGF switching.
Mejias reports in this issue3 a new mech-
anism and therapeutic effect by targeting
endogenous pigment epithelium-derived
factor (PEDF) in bile duct-ligated portal
hypertensive rats. PEDF belongs to the
subgroup of the so-called non-inhibitory
serpins that lack the protease inhibitory
activity but which interacts with a variety
of cellular components and signalling cas-
cades. For this reason, PEDF is best charac-
terised as a multifunctional protein with
therapeutic effects in many diseases.4 5
The authors demonstrated that by
employing an adenoviral-mediated gene
transfer of PEDF, which enhanced the
expression of PEDF, only resulted in inhib-
ition of neoangiogenesis. This is import-
ant, since any drug used to treat or prevent
PHT should ideally inhibit neoangiogen-
esis without affecting the normal vessels.
Moreover, in this experimental approach,
by applying prevention trials and interven-
tion trials, authors showed to diminish (1)
signiﬁcantly liver ﬁbrosis by upregulation
of matrix metalloproteinase-2 (MMP-2),
(2) portosystemic collateralisation and (3)
portal pressure in bile duct-ligated rats. To
translate these data to man, the authors
investigated PEDF localisation in
HCV-related cirrhosis, and observed that
PEDF was predominantly overexpressed in
regenerative micronodules, at the interface
between liver parenchyma and highly neo-
vascularised ﬁbrous septa. These
PEDF-positive regions also correlated with
high expression levels of VEGF. This
observation was further substantiated with
in vivo data where the authors showed a
spatio-temporal PEDF expression that
followed the upregulation of VEGF in
bile duct ligation (BDL)-ligated rats,
CCl4-induced cirrhotic livers, and during
neoangiogenesis in the mesentery. Thus,
this observation demonstrates an import-
ant element in underlying the mechanism
of PEDF therapy to counteract
VEGF-related actions during neoangiogen-
esis. Of note, in the BDL experimental
model, PEDF was particularly effective
when administered during the early phase
of liver disease (prevention trial), consist-
ent with its capability to interfere, in the
liver, with the ﬁbrogenesis/angiogenesis
couple and, in the mesentery, with the neo-
vascular response at the time of its
maximal expression (see ﬁgure 1). These
data indicate that, if translated into clinical
usage, such drugs would interfere with
neoangiogenesis at an early stage of PHT.
At present, we have various drugs that
target almost exclusively the splanchnic
and intrahepatic vascular tone and which
are used clinically to treat the complica-
tions of PHT. However, there are two
major unmet clinical needs: namely to
halt or prevent the rise of portal pressure
before clinically signiﬁcant PHT devel-
ops, and to increase efﬁcacy, once PHT
has developed, with new therapeutic
targets. With regard to the ﬁrst point,
longitudinal studies in cirrhotic patients
with baseline haemodynamic assessment
have clearly demonstrated that all PHT
complications do not develop until the
hepatic venous pressure gradient
(HVPG) exceeds 10 mm Hg, namely the
range of clinically signiﬁcant PHT.6
Therefore, a drug which is able to
Figure 1 Pigment epithelium-derived factor (PEDF) gene transfer as a novel therapeutic agent.
PEDF is overexpressed in the liver and mesenteric vascular bed in animal models of portal
hypertension and cirrhosis. PEDF and vascular endothelial growth factor (VEGF) are
unidirectionally upregulated and correlate with mesenteric neovascularisation and liver
ﬁbrogenesis during cirrhosis. In vivo PEDF gene transfer mediated by adenoviral vectors (AdPEDF)
effectively suppresses mesenteric pathological angiogenesis and intrahepatic ﬁbrogenesis in bile
duct ligation (BDL) rats, leading to a signiﬁcant decrease in portal pressure.
1Internal Medicine and Hepatology, University Campus
Bio-Medico of Rome, Rome, Italy; 2Institute for Liver &
Digestive Health, University College London (UCL),
Royal Free Hospital, London, UK
Authors contributed equally.
Correspondence to Dr Krista Rombouts, Division of
Medicine, Royal Free Hospital & University College
London, Institute for Liver & Digestive Health, Rowland
Hill Street, London NW3 2PF, UK; k.rombouts@ucl.ac.uk
Vespasiani-Gentilucci U, et al. Gut Month 2014 Vol 0 No 0 1
Commentary
 Gut Online First, published on June 25, 2014 as 10.1136/gutjnl-2014-307583
Copyright Arti le author ( r their employer) 2014. Produced by BMJ Publishing Group Ltd (& BSG) under licence. 
group.bmj.com on November 26, 2014 - Published by http://gut.bmj.com/Downloaded from 
prevent an increase of portal pressure
from the subclinical to the clinically sig-
niﬁcant range would prevent many of the
sequelae we observe.
Since neoangiogenesis actively contri-
butes to PHT from the ﬁrst steps of its
development,1 drugs with antiangiogenic
properties are attractive candidates to
prevent PHT.7 However, the development
of clinical studies to investigate this has
been hampered by drug toxicity and the
concerns about interfering with physio-
logical angiogenesis.7 The results pre-
sented by Mejias launches PEDF as a
promising agent with the potential ability
to affect portal pressure by speciﬁcally
targeting pathological angiogenesis.
Conversely, the signiﬁcantly lower activity
demonstrated by PEDF when given in a
more advanced phase of liver disease raises
some doubts concerning its potential to
add something for the treatment of clinic-
ally signiﬁcant PHT. However, since a
modest effect on portal pressure is
observed even in advanced cirrhosis, the
combination of PEDF with vasoactive
drugs deserves further experimental inves-
tigation, with the hope that working simul-
taneously on more therapeutic targets will
maximise the impact on portal pressure.
In conclusion, the data presented in this
study highlights again the importance of
targeting VEGF-driven angiogenesis and
reveals new important insights into the
molecular working mechanism of PEDF as
a possible antiangiogenic and antiﬁbrotic
agent in the treatment of early phase PHT.
Hence, the next step should be trying to
translate these ﬁndings into clinical prac-
tice, where PEDF needs to conﬁrm its cap-
ability to halt the rise of portal pressure,
and to prove it can add something, eventu-
ally in association with or without non-
selective β-blockers (NSβB)8 and/or anti-
inﬂammatory agents,9 before clinical sig-
niﬁcant PHT has developed.
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